SCHEMBL15946013

SCHEMBL15946013

CCCC(O)c1cccc(NS(=O)(=O)C(CCC)CCC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CACNA1F O60840 1/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
DRD3 P35462 1/20 0.40
CACNA1D Q01668 1/20 0.40
KCNH2 Q12809 1/20 0.40
CACNA1S Q13698 1/20 0.40
CACNA1C Q13936 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ADRB3 P13945 6/20 0.37
ADRA1A P35348 4/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3130816 0.92 CA1 (0.40) CA1CA2CACNA1FCHRM2ADRA2B
SCHEMBL3135276 0.87 CA1 (0.36) CA1CA2CACNA1FCHRM2ADRA2B
SCHEMBL2150529 0.82 CA1 (0.41) CA1CA2ADRB3ADRA1AMEN1
SCHEMBL15946008 0.81 AURKA (0.47) CA1CA2CACNA1FCHRM2ADRA2B
SCHEMBL15946028 0.81 HTR6 (0.50) ADRB3MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL15946030 0.78 ADRB3 (0.49) ADRB3ADRA1ALMNA
SCHEMBL15945990 0.77 ADRB3 (0.49) ADRB3ADRA1ALMNA
SCHEMBL21239626 0.77 KEAP1 (0.48) CA1CA2MEN1KMT2AALDH1A1
SCHEMBL15946023 0.76 CA1 (0.60) CA1CA2KDM4EMEN1KMT2A
SCHEMBL15946025 0.76 ALDH1A1 (0.43) CA1CA2ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2016-05-26 US disclosed
US-9193669-B2 Compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2015-11-24 US disclosed
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145198-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 CA1 4789/4885CA2 1745/4885CACNA1F 3030/4885
US-20140228443-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, ALDH1A2 CA1 4789/4885CA2 1745/4885CACNA1F 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.